# US 11,026,967 B2 · Composition for suppressing or preventing abnormality in intestinal environment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,026,967 B2
- Document ID: US11026967B2
- Status: Granted
- Kind: B2
- Application number: 16/085,050
- Filed: 2018-03-30
- Published: 2019-06-20
- Granted: 2021-06-08
- Earliest claimed: 2018-03-30
- Assignees: Miz Co., Ltd.; Osaka University
- Applicants: MiZ Company Limited; Osaka University
- Inventors: Mitsunori Ikeda; Kentaro Shimizu; Hiroshi Ogura; Shinichi Hirano; Ryosuke Kurokawa
- Web page: https://patentgrep.com/patent/US11026967B2

## CPC

- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/10: Antimycotics
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This application provides a composition comprising hydrogen gas or dissolved hydrogen as an active ingredient for suppressing or preventing abnormality in the intestinal environment of a subject, wherein the abnormality is selected from the group consisting of bacterial translocation and bacterial species composition abnormality of intestinal flora.

## Claims

### Claim 1

A method of suppressing or preventing bacterial translocation in the intestinal environment in a subject, comprising administering to a subject in need thereof a composition comprising dissolved hydrogen as an active ingredient, such that bacterial translocation is suppressed or prevented in the intestinal environment of the subject.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the bacterial translocation leads to development or worsening of sepsis, systemic inflammatory response syndrome (SIRS), and multiple organ failure (MOF) syndrome.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the composition improves intestinal tissue damage of the subject.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the composition is in the form of a hydrogen-dissolved liquid.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the hydrogen-dissolved liquid has a hydrogen concentration of 1 to 10 ppm.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the composition is administered to the subject by an oral route.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the composition is produced in situ using a device for preparing hydrogen-dissolved liquids at the time of administration.

### Claim 8 (depends on 1)

The method according to claim 1, wherein suppression of the bacterial translocation leads to: (1) suppressing bacterial species composition abnormality of intestinal flora; and/or (2) suppressing or improving development or worsening of sepsis, systemic inflammatory response syndrome (SIRS), and multiple organ failure (MOF) syndrome.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the bacterial species composition abnormality is an abnormal increase or decrease in at least one bacterial species in the intestinal flora.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the bacterial species composition abnormality leads to development of a dysbiosis-related disease.